Seegene Challenges Virus-Only Testing Standards in Pediatrics

Analysis of 260,000 pediatric test results over 42 months revealed that relying on single-pathogen panels creates a dangerously incomplete diagnostic picture. While viral panels show an 87% positivity rate, they overlook pneumonia-causing bacteria in the vast majority of those cases. Conversely, bacterial testing misses viral co-detections in 88% of instances. This diagnostic blind spot persists despite symptoms like fever and cough appearing identical regardless of the underlying pathogen type.

Seegene’s data suggests that current global testing demand remains skewed, with 80% of volume focused on viral detection alone. By utilizing its STAgora statistical platform, the company aims to demonstrate that comprehensive testing—which flags multiple pathogens in a single specimen—offers a 96% positivity rate, with 82% of those results confirming the presence of at least two distinct pathogens. The upcoming Global Million Clinical Study seeks to codify these findings into a new standard for clinical practice, moving away from narrow diagnostics toward a more holistic view of respiratory illness in young patients.